Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of reducing fever01:22

Methods of reducing fever

1.6K
The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
1.6K
Increased Body Temperature01:25

Increased Body Temperature

7.7K
A body temperature above  38°C  (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in...
7.7K
Types of Fever01:25

Types of Fever

1.5K
Fever can be triggered by several factors, including infections, nervous system disorders, certain cancers, blood diseases like leukemia, embolism, thrombosis, heatstroke, dehydration, surgical trauma, crushing injuries, and allergic reactions.
Here are the different types of fever:
1.5K
Patterns of Fever01:26

Patterns of Fever

4.5K
Before understanding the types and patterns of fever, it is essential to know its phases.
4.5K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.8K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

898
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
898

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Authoritarian attitudes and the perceived scientific legitimacy of anthroposophic medicine: A survey of attitudes on complementary and alternative medicine in Austria.

PloS one·2026
Same author

Trials and tribulations of responsible people trying to uphold scientific standards.

Research integrity and peer review·2026
Same author

WHO's category mistake.

Lancet (London, England)·2025
Same author

Spinal manipulations for migraine: an updated systematic review and meta-analysis of randomized clinical trials.

Systematic reviews·2024
Same author

Is Osteopathic Manipulative Treatment Clinically Superior to Sham or Placebo for Patients with Neck or Low-Back Pain? A Systematic Review with Meta-Analysis.

Diseases (Basel, Switzerland)·2024
Same author

An evidence map on traditional medicine across health outcomes.

Integrative medicine research·2024
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.4K

Feverfew for preventing migraine.

Barbara Wider1, Max H Pittler, Edzard Ernst

  • 1Institute of Health Research, University of Exeter Medical School, South Cloisters, room 1.36, St Luke's Campus, Exeter, UK, EX1 2LU.

The Cochrane Database of Systematic Reviews
|April 21, 2015
PubMed
Summary
This summary is machine-generated.

Feverfew (Tanacetum parthenium L.) may offer a slight reduction in migraine frequency, but evidence quality is low. More rigorous trials are needed to confirm its effectiveness and safety for migraine prevention.

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.7K
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.9K

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.4K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.7K
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.9K

Area of Science:

  • Herbal medicine
  • Neurology
  • Systematic Review

Background:

  • Feverfew (Tanacetum parthenium L.) extract is a herbal remedy utilized for migraine prevention.
  • This review updates a previous Cochrane Database of Systematic Reviews publication from 2004.

Purpose of the Study:

  • To systematically review evidence from double-blind randomized controlled trials (RCTs) on the efficacy and safety of feverfew monopreparations versus placebo for migraine prevention.
  • To assess clinical outcomes and adverse events associated with feverfew use in migraine patients.

Main Methods:

  • Searched CENTRAL, MEDLINE, EMBASE, and AMED databases up to January 2015, along with manufacturer contact and bibliography checks.
  • Included randomized, placebo-controlled, double-blind trials assessing feverfew efficacy for migraine prevention using clinical outcome measures.
  • Extracted data on patients, interventions, methods, outcomes, and adverse events; assessed risk of bias and methodological quality.

Main Results:

  • Six trials (561 patients) met inclusion criteria; one new rigorous trial was added.
  • The new trial showed feverfew reduced migraine frequency by 0.6 attacks/month compared to placebo (low quality evidence).
  • No statistically significant differences were found for secondary outcomes; mild gastrointestinal complaints were the most common adverse events.

Conclusions:

  • A single larger, rigorous study suggests a modest benefit of feverfew in reducing migraine frequency.
  • The overall evidence remains mixed and inconclusive, necessitating confirmation in larger, high-quality trials.
  • Feverfew appears to have no major safety concerns, with only mild, transient adverse events reported.